ASX Announcement | 8 December 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Corporate Presentation for December Investor Webinar

Sydney 8 December 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide the following corporate presentation for today's Investor Webinar.

Noxopharm CEO, Dr Graham Kelly will provide an updated overview of the Company's recent corporate and R&D activities, proposed use of the $23 million funds recently raised, and the Company's plans and expectations for 2021. A recording of the webinar will be made available on the Noxopharm website later this week.

Date and Time: Tuesday 8 December, 2020 at 2pm AEDT

Attendees will need to pre-register via the following link:

Noxopharm Investor Webinar 8 December 2020 at 2pm AEDT

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking the development of septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.


NOXOPHARM
Noxopharm Limited (ASX:NOX)
WEBINAR PRESENTATION
DECEMBER 2020
Discover
Develop
Deliver

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Our single-minded objective …….

- ☛ is to prove that **Veyonda®**
- ☛ is the answer to unlocking the power of the immune system to fight cancer
- ☛ allowing the 3 main forms of cancer therapy - **immuno-oncology**, **radiotherapy**, **chemotherapy** - to reach their full potential
- ☛ identifying **Noxopharm** as a highly valuable industry partner

Key R&D achievements in 2020 .....



We go into 2021 …….

- ☛ with a strong cash position

  *(based on **$23M** CR and anticipated R&D Rebate)*

- ☛ providing a full 12-month runway
- ☛ to meet aim of attaining proof-of-concept of **Veyonda** as a major new drug prospect



Veyonda joins the new wave of cancer immuno-oncology (I-O) therapies …….

NOXOPHARM

- ☛ that aim to restore the body's immune system to fight cancer
- ☛ are the acknowledged future of cancer therapy
- ☛ re-activating the immune system is readily achieved
- ☛ the problem is getting the reactivated immune cells back inside the tumours where they can kill the cancer cells
- ☛ the challenge facing the current US$30 billion p.a. I-O therapy market is that most human tumours block that re-entry. NOX believes **Veyonda** is the leading candidate to overcome this problem

Restoring immune function to tumours



All healthy tissues contain immune cells (T cells) T

whose role is to detect and eliminate any abnormal cells



Emerging cancer cells

produce high levels of S1P **(sphingosine-1-phosphate)** that drive the immune cells out of the tissue



With tumour now fully established, ongoing high S1P levels keep immune cells excluded

Cancer cells now free to grow in the absence of immune cells

= **COLD tumour**



Veyonda block S1P production by cancer cells

With S1P levels down and the shield removed, immune cells now enter and repopulate the tumour

Immune cells now able to kill cancer cells

= **HOT tumour**

Employing the unique ‘COLD to HOT’ Veyonda function



Source: Enhancing Immunotherapy: The Race to Make “Cold” Tumors “Hot”. https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/)

PD-1 therapy	**IONIC Program** **Veyonda + checkpoint (PD-1) inhibitors**
Radio-therapy	**DARRT Program** **Veyonda + (external beam) radiotherapy**
Radio-therapy	**LuPIN Program** **Veyonda + (intravenous) radiotherapy**
Chemo-therapy	**CEP Program** **Veyonda + chemotherapy**

Employing the unique ‘COLD to HOT’ Veyonda function



Source: Enhancing Immunotherapy: The Race to Make “Cold” Tumors “Hot”. https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/)

PD-1 therapy

IONIC Program
Veyonda + checkpoint (PD-1)inhibitors

2021/2022

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

Radio-therapy

LuPIN Program
Veyonda + (intravenous) radiotherapy

Chemo-therapy

CEP Program
Veyonda + chemotherapy

PD-1 therapy

IONIC Program
Veyonda + checkpoint inhibitors

2019 sales of checkpoint inhibitors **US$22 billion**

- Keytruda® Merck
- Opdivo ® Bristol-Myers Squibb
- Yervoy ® Bristol-Myers Squibb

10-30% response rates in 7 cancers (eg. lung, melanoma, kidney, bladder)

<5% response rates in most other cancers

COLD tumours identified as major cause of non-response

Major Licensing and M&A activity to achieve higher response rates shifting sales to predicted US$100 + billion p.a.

Search for Checkpoint Inhibitor partners



Fig. 1 | Trends in immuno-oncology drug licensing. 2018 was the biggest year yet for immuno-oncology (IO) drug licensing in terms of deal size and volume. IO licensing deal size increased in value by 51% from 2017 to 2018, while volume increased by 8%. Only licensing deals for drugs or drug platforms applicable to IO therapeutics were included. Data from Cortellis Deals Intelligence from Clarivate Analytics.

2018 15x Licensing Deals > US$1 billion

Buyer	Seller	Total deal value
BMS	Nektar Therapeutics	**US$3,630 B**
Merck	Eisai	**US$5,755 B**

PD-1 therapy

IONIC Program
Veyonda + checkpoint inhibitors

NOXOPHARM

IONIC-1

Veyonda® + checkpoint inhibitor

Bristol-Myers Squibb	**(NYSE:BMY)**
Market cap	**US$145 billion**
Pharma ranking	**11th**
2019 sales	**US$26 billion**
2019 Opdivo sales	**US$8 billion**
2019 Celgene acquisition	**US$74 billion**

Immuno-Oncology With NOX66 In Combination

Veyonda® + nivolumab (Opdivo®)
(Bristol Myers Squibb)

A Phase I/II study involving both NOX and Bristol-Myers Squibb

PD-1 therapy

IONIC Program
Veyonda + checkpoint inhibitors

NOXOPHARM

IONIC-1

Phase I/II study
Investigator-initiated
~30 patients
3 Australian hospitals
Early-Q1 2021 start

Clinical objective #1
Improve low (10-30%) response rates to Opdivo in responsive cancers (eg. lung, melanoma, bladder, kidney)

Cohort 1. Patients recently treated with Opdivo® with mild disease progression

Clinical objective #2
Achieve responses in remaining cancers where Opdivo® not currently used due to very poor response rates (eg. prostate, ovarian, pancreatic, sarcoma etc)

Cohort 2. Opdivo® naive patients

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

NOXOPHARM

Direct and Abscopal Response to Radiotherapy

Transforming a local anti-cancer effect of radiation into a whole-of-body anti-cancer effect (**abscopal response**)



Objectives:

1. To convert the **abscopal response** from a very rare phenomenon (< 1 in 100,000) to a more commonplace event (~50% of cancer patients)
2. To produce long-term remission in metastatic cancers where survival prospects currently are poor

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

DARRT Program

Radiotherapy

4-step DARRT process:
Step 1. Radiation applied to single tumour
Step 2. Radiation activates immune cells
Step 3. Veyonda augments that local immune response
Step 4. Veyonda then spreads that immune response to all other tumours throughout the body



Resolution of Irradiated tumour

Standard response



Partial abscopal response

Complete abscopal response

Abscopal response

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

- DARRT-1 **Completed** 25 men late-stage progressive **prostate cancer**
- Metastatic castration-resistant prostate cancer (mCRPC)
- No remaining standard treatment options
- Low-dose (palliative) radiotherapy (RT) to single soft tissue tumour
- Treatment with low-dose RT (5 days) and Veyonda® (14 days)



Bone scan with metastatic disease

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

In patients evaluable after 6 months* …..



* 15 patients eligible for RECIST; 16 for PSA and pain

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy

- **DARRT-2 Phase 2 study** 150 - 200 patients multi-national Parexel CRO
- Late-stage cancer. No remaining standard treatment options
- **Final planning current. Enrolment to start H1 2021**
- Prostate cancer, breast cancer, lung cancer
- Boosted therapy compared to DARRT-1 (2400 mg vs 1200 mg; multiple cycles of Veyonda vs 1 cycle

Radio-therapy

LuPIN Program
Veyonda + (intravenous) radiotherapy

NOXOPHARM

- **LuPIN program** = **Veyonda** + **^{177}lutetium-PSMA-617** for late-stage prostate cancer
- **^{177}lutetium-PSMA-617** acquired by **Novartis** in 2018 in **US$6 billion** transaction
- **St Vincent's Hospital Sydney** testing ability of LuPIN therapy to boost modest survival effect of Novartis drug alone
- **LuPIN-1 =** Phase 2 study in 56 men with late-stage cancer that has progressed on all forms of therapy
- First report of median overall survival from first **32 men** (**400/800 mg** Veyonda) highly encouraging at **17.1 months**
- Median overall survival from all **56 men** (**400/800/1200 mg** Veyonda) to be reported **Feb 2021**

Objectives

Over the next 2.5 years, with a modest investment of shareholder funds, to show that ….

IONIC	**Veyonda increases the response rate to nivolumab (Opdivo) (BMS), establishing its potential to boost checkpoint inhibitor drug sales well above current US$22 billion p.a.**
DARRT	**Veyonda + radiotherapy and the abscopal response is a valid, cost-effective alternative form of I-O treatment for a range of solid cancers**
LUPIN	**Veyonda boosts the response rate in advanced prostate cancer to ^{177}Lu-PSMA-617 (Novartis)**
PHARMORAGE	**The Company's technology platform holds the potential to develop a family of new drugs for the treatment of septic shock, inflammatory diseases and autoimmune diseases**

So building a highly valuable and compelling acquisition/partnering target

Discover  Develop  Deliver 

NOXOPHARM

An I-O therapy to transform the management of cancer

www.noxopharm.com

Email: info@noxopharm.com
Phone: (+61) 2 9144 2223

https://www.linkedin.com/company/noxopharm-limited
https://twitter.com/noxopharm

Media Enquiries
The Capital Network
Julia Maguire
+61 2 8999 3699
julia@thecapitalnetwork.com.au